What is the optimal apalutamide regimen for an elderly male nursing‑home resident with prostate cancer?

Apalutamide 240 mg daily with ADT is the optimal regimen for an elderly nursing home resident with metastatic prostate cancer

For elderly nursing home residents with metastatic prostate cancer, apalutamide 240 mg daily combined with androgen deprivation therapy (ADT) represents a standard of care that maintains efficacy and tolerability across all age groups, including those ≥80 years. 1, 2

Evidence Supporting Use in Elderly Patients

The 2021 ASCO guideline establishes apalutamide plus ADT as one of four separate standards of care for noncastrate metastatic prostate cancer, with strong evidence quality 1. This recommendation applies regardless of age, as demonstrated by post-hoc analyses from the pivotal TITAN trial showing consistent benefit across age groups.

Age-specific efficacy data from TITAN demonstrates that apalutamide maintains effectiveness in elderly patients:

• Patients <65 years: HR 0.57 (95% CI 0.40-0.80)
• Patients 65-79 years: HR 0.70 (95% CI 0.54-0.91)
• Patients ≥80 years: HR 0.74 (95% CI 0.40-1.39) 3

The hazard ratios consistently favor apalutamide across all age groups, indicating preserved efficacy in the elderly population typical of nursing home facilities.

Dosing and Administration

The standard dose is apalutamide 240 mg (four 60 mg tablets) taken orally once daily with ongoing ADT 4. Key pharmacokinetic considerations for elderly patients:

• No dose adjustment required based on age (studied in patients 18-94 years) 4
• Can be taken with or without food (no clinically relevant changes in absorption) 4
• Tablets may be dispersed in applesauce if swallowing is difficult, maintaining bioavailability 4
• Steady-state achieved after 4 weeks with mean half-life of approximately 3 days 4

Safety Profile in Elderly Nursing Home Residents

The most critical safety consideration is the increased incidence of grade 3-4 fatigue in patients ≥80 years (19% vs 5% in younger patients), while other adverse events remain comparable across age groups 3. This finding is particularly relevant for nursing home residents who may have baseline functional limitations.

Common Adverse Events to Monitor:

• Rash: 24% overall (15.7% in real-world Japanese data), typically manageable 2, 5
• Fractures: 11% (versus 6.5% with placebo) - critical given nursing home fall risk 6, 2
• Hypothyroidism: 8% (versus 2% with placebo) 2
• Fatigue: Higher in elderly, requiring close monitoring 3

Cardiovascular Considerations:

Apalutamide causes QTc prolongation (maximum mean change 12.4 ms) 4. Given that elderly nursing home residents often have cardiovascular comorbidities, baseline and periodic ECG monitoring is prudent, particularly in patients on other QT-prolonging medications.

Contraindications to Standard ADT in Elderly

Importantly, ADT alone should NOT be routine practice in elderly patients with localized prostate cancer 7. A cohort study of 19,271 elderly men with T1-T2 localized prostate cancer showed no survival benefit with ADT versus observation 7. However, this does not apply to metastatic disease, where treatment intensification with apalutamide plus ADT is indicated.

Practical Management Algorithm for Nursing Home Setting

Step 1: Confirm metastatic disease status

• Metastatic castration-sensitive prostate cancer (mCSPC): Apalutamide 240 mg daily is category 1 preferred 1, 2
• Non-metastatic castration-resistant prostate cancer (nmCRPC) with PSA doubling time ≤10 months: Apalutamide 240 mg daily is category 1 preferred 2

Step 2: Assess fitness for treatment

• If patient can tolerate oral medication and has life expectancy >6 months: Proceed with apalutamide
• If severe baseline fatigue or ECOG ≥3: Consider whether treatment intensification is appropriate versus ADT alone

Step 3: Implement bone health measures Given 11% fracture risk and nursing home fall risk:

• Calcium 1200 mg daily and vitamin D3 800-1000 IU daily 7
• Consider bone-modifying agents (though not proven beneficial in noncastrate bone metastases) 1
• Fall prevention strategies
• Baseline and periodic bone density assessment

Step 4: Monitor for adverse events

• Weeks 1-4: Weekly assessment for rash (most common early adverse event)
• Month 1: TSH (thyroid function), fatigue assessment
• Month 3: PSA response (expect median PSA 0.8 ng/mL with apalutamide vs 3.4 ng/mL with bicalutamide) 5
• Ongoing: Monthly fatigue assessment, fall risk evaluation

Quality of Life Considerations

Apalutamide maintains health-related quality of life compared to ADT alone, with no significant deterioration across age groups 3, 8. This is particularly important for nursing home residents where quality of life is paramount. The TITAN trial demonstrated that 68% of patients achieved undetectable PSA (<0.2 ng/mL) with apalutamide versus 32% with ADT alone 4, translating to meaningful disease control without compromising daily function.

Alternative Considerations

While apalutamide is preferred, enzalutamide and abiraterone plus prednisone represent equivalent alternatives if apalutamide is unavailable or not tolerated 1. However, abiraterone requires twice-daily prednisone co-administration, which may complicate medication management in nursing home settings. Bicalutamide is inferior, with significantly shorter time to castration-resistant disease (24-month CRPC-free probability: 68.2% with apalutamide vs 39.8% with bicalutamide) 5.

Common Pitfalls to Avoid

1. Do not withhold apalutamide based solely on chronological age - efficacy is preserved in patients ≥80 years 3
2. Do not use ADT alone for metastatic disease in fit elderly patients - this represents undertreatment 1
3. Do not overlook fracture prevention - implement bone health measures proactively given 11% fracture risk 6, 2
4. Do not ignore drug-drug interactions - apalutamide is a strong CYP3A4 inducer affecting multiple medications common in elderly patients 4
5. Do not assume tablets cannot be crushed - they can be dispersed in applesauce if needed 4

Drug Interactions Critical for Nursing Home Polypharmacy

Apalutamide is a moderate-to-strong CYP3A4 and CYP2B6 inducer 4:

• Decreases midazolam AUC by 92% (affects benzodiazepines commonly used in nursing homes)
• Decreases warfarin AUC by 46% (requires INR monitoring if on anticoagulation)
• Decreases omeprazole AUC by 85% (may affect proton pump inhibitors)

Review all concomitant medications and adjust doses accordingly, particularly for drugs with narrow therapeutic indices.